Retrospective Cohort Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1321-1331
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1321
Table 5 Univariate models for recurrence and death outcome
VariableHazard ratio for recurrence
Hazard ratio for death
HR (95%CI)P valueHR (95%CI)P value
MELD score (per point)1.03 (0.98-1.09)0.261.05 (1.003-1.09)0.04a
Diameter of the largest tumor at time of transplant (per cm)1.27 (1.04-1.56)0.02a1.21 (1.03-1.41)0.02
Tumor number at time of transplant1.001 (0.73-1.37)1.000.93 (0.72-1.20)0.57
Neutrophil lymphocyte ratio > 42.24 (1.17-4.26)0.02a1.66 (1.004-2.73)0.048a
Hypothyroidism1.26 (0.55-2.85)0.591.54 (0.82-2.90)0.18
BALAD components
Albumin (per g/dL)0.75 (0.41-1.38)0.360.69 (0.43-1.13)0.14
Bilirubin (per mg/dL)1.03 (0.98-1.09)0.211.04 (0.995-1.08)0.08
AFP: > 400 ng/mL2.42 (1.18-5.00)0.02a3.27 (1.84-5.80)< 0.001b
AFP-L3 > 15%1.86 (0.98-3.52)0.0561.88 (1.14-3.09)0.01a
DCP > 1.2 ng/mL2.83 (1.42-5.61)0.003b2.40 (1.43-4.04)< 0001b
BALAD Score
0ReferenceReference
10.70 (0.20-2.47)0.581.14 (0.40-3.23)0.81
21.18 (0.37-3.75)0.782.01 (0.75-5.38)0.17
31.99 (0.62-6.36)0.242.73 (0.99-7.51)0.052
42.97 (0.84-10.58)0.094.68 (1.52-14.36)0.007b
55.02 (0.92-27.54)0.0617.40 (3.81-79.47)< 0.001b
BALAD Score (per increase of 1)1.48 (1.15-1.91)0.002b1.59 (1.28-1.97)< 0.001b
BALAD-2 Score
1ReferenceReference
20.41 (0.12-1.32)0.131.07 (0.50-2.28)0.86
31.53 (0.66-3.54)0.321.76 (0.87-3.54)0.11
42.17 (0.90-5.25)0.092.45 (1.16-5.17)0.02a
BALAD-2 Score (per increase of 1)1.45 (1.06-1.98)0.02a1.38 (1.09-1.76)0.008b
Within Milan criteria at diagnosis1.69 (0.84-3.41)0.142.17 (1.25-3.78)0.006b
Within UCSF criteria at diagnosis1.85 (0.85-4.05)0.123.19 (1.75-5.84)< 0.001b
Within Milan criteria at transplant1.24 (0.59-2.62)0.571.06 (0.57-1.95)0.86
Within UCSF criteria at transplant0.33 (0.05-2.43)0.280.68 (0.21-2.17)0.51
z-GALAD1.12 (1.03-1.21)0.006b1.12 (1.06-1.19)< 0.001b
GALAD score3.01 (1.14-7.91)0.03a3.22 (1.48-7.00)0.003b
AFP model cutoff > 2 (explant)2.82 (1.47-5.41)0.002b2.83 (1.67-4.82)< 0.001b
AFP model (per increase of 1, explant)1.42 (1.20-1.68)< 0.001b1.34 (1.16-1.54)< 0.001b

  • Citation: Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, Mara KC, Harmsen WS, Theobald JP, Peters BE, Balsanek JG, Ward MM, Giama NH, Venkatesh SK, Harnois DM, Charlton MR, Yamada H, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol 2018; 24(12): 1321-1331
  • URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1321.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1321